In vitro susceptibility of oral Candida to seven antifungal agents.
about
Candida pseudorugosa sp. nov., a novel yeast species from sputum.Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasisNanodisks protect amphotericin B from ultraviolet light and oxidation-induced damage.Relationship between Antifungal Activity against Candida albicans and Electron Parameters of Selected N-Heterocyclic ThioamidesCurrent treatment of oral candidiasis: A literature review.Novel Nystatin A₁ derivatives exhibiting low host cell toxicity and antifungal activity in an in vitro model of oral candidosis.Potent in vitro antifungal activities of naturally occurring acetylenic acids.Treatment strategies for oropharyngeal candidiasis.In vitro susceptibility of e.faecalis and c.albicans isolates from apical periodontitis to common antimicrobial agents, antibiotics and antifungal medicaments.Evaluation of virulence factors and antifungal susceptibility patterns of different Candida species isolated from the female camel (Camelus dromedarius) genital tract.Antifungal suscepitibility profile of candida spp. oral isolates obtained from denture wearers.Anti-Candida activity of 1-18 fragment of the frog skin peptide esculentin-1b: in vitro and in vivo studies in a Caenorhabditis elegans infection model.Minimum inhibitory concentrations of amphotericin B against Candida krusei isolates from a French teaching hospital laboratory: a retrospective study over 8 years.Susceptibilities of Candida albicans mouth isolates to antifungal agents, essentials oils and mouth rinses.Fluconazole impacts the extracellular matrix of fluconazole-susceptible and -resistant Candida albicans and Candida glabrata biofilms.
P2860
Q31064491-248B171F-5653-4E1F-A5A3-5209CF785C12Q33359301-2894996B-133C-4E8F-A299-035CF5DEF998Q33946948-1F68B706-38E7-4FF4-B6F9-5037EDDF003AQ34228920-AE816082-2D5B-4E3B-B844-6FDC25F4EA64Q35034247-50239D9F-B0BD-44E9-B52B-8F736D324D77Q35187151-25B1DD4F-F6F8-4B90-B1A3-25FE69DD8E48Q36744749-B938C496-699E-45F5-BCB4-71E3DE38F16CQ37510887-A02C4DD6-3DAF-4579-8AAA-BC92172F66F9Q37537740-4538EA81-B0B2-4499-8D64-562EE7EC792FQ41119156-015FE941-9ADA-411F-ABB6-8D8076D43913Q42593612-74D54F67-4E95-4072-A7C4-F758EA5A4DB4Q42708452-A7155423-1495-47B2-9194-FF2528171D90Q47877472-0148D510-5043-415A-9753-631DE65C3EFAQ50975501-DC60B4FE-0F3D-495A-908F-81DEB18D3788Q55048944-A2595431-1067-48E7-894F-7F6059FBE043
P2860
In vitro susceptibility of oral Candida to seven antifungal agents.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
In vitro susceptibility of oral Candida to seven antifungal agents.
@en
In vitro susceptibility of oral Candida to seven antifungal agents.
@nl
type
label
In vitro susceptibility of oral Candida to seven antifungal agents.
@en
In vitro susceptibility of oral Candida to seven antifungal agents.
@nl
prefLabel
In vitro susceptibility of oral Candida to seven antifungal agents.
@en
In vitro susceptibility of oral Candida to seven antifungal agents.
@nl
P2093
P2860
P1476
In vitro susceptibility of oral Candida to seven antifungal agents.
@en
P2093
P2860
P304
P356
10.1111/J.1399-302X.2005.00236.X
P577
2005-12-01T00:00:00Z